The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
 
Michael C. Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Novartis; Theseus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Karma Oncology; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Hans Gelderblom
Research Funding - Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); Merck (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG
 
Patrick Schöffski
Honoraria - Blueprint Medicines; Boehringer Ingelheim; Deciphera
Consulting or Advisory Role - Adaptimmune (Inst); Adcendo; Advance Medical/Teladoc Health (Inst); Blueprint Medicines; Blueprint Medicines (Inst); Boehringer Ingelheim; CRT Pioneer Fund LP; Curio Science; Deciphera; Ellipses Pharma; Ellipses Pharma (Inst); Exelixis; Guided Clarity; Intellisphere (Inst); Medscape; Modus Outcomes; SQZ Biotechnology; Studiecentrum voor Kernenergie (SCK CEN); Transgene; Transgene (Inst); Ysios Capital
Research Funding - CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Ipsen (Inst); MSD (Inst)
 
Margaret von Mehren
Consulting or Advisory Role - deciphera; GlaxoSmithKline
Research Funding - ASCO (Inst); Deciphera (Inst); Genmab (Inst); Gradalis (Inst); Novartis (Inst); Solaris Health (Inst)
Patents, Royalties, Other Intellectual Property - cell line
Travel, Accommodations, Expenses - Deciphera
Other Relationship - NCCN
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Acceleron Pharma; Aimmune; Alnylam; Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Global Blood Therapeutics; GW Pharmaceuticals; Madrigal Pharmaceuticals; Moderna Therapeutics; Myovant Sciences; Opthea; Orphazyme; Sangamo Bioscience; Twist Bioscience; UniQure; Vertex; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; Specialised Therapeutics; Targovax
Consulting or Advisory Role - Center for Emerging & Neglected Diseases (CEND); Deciphera; Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Specialised Therapeutics; Targovax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); Merck Serono (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme; Sanofi
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Pfizer; Roche/Genentech
 
Jonathan C. Trent
Consulting or Advisory Role - Agios; Bayer; Blueprint Medicines; C4 Therapeutics; Daiichi Sankyo; Deciphera; Epizyme; Janssen; Lilly; Novartis
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst)
 
Axel Le Cesne
Honoraria - Bayer; PharmaMar
 
Ying Su
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Julie Nicole Meade
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Tao Wang
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera; Pfizer
 
Matthew L. Sherman
Employment - Deciphera; Pieris Pharmaceuticals
Leadership - Deciphera
Stock and Other Ownership Interests - Deciphera; Pieris Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Acceleron Pharma
Travel, Accommodations, Expenses - Deciphera; Pieris Pharmaceuticals
 
Rodrigo Ruiz-Soto
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera; Immunogen
Patents, Royalties, Other Intellectual Property - I am an inventor in 3 patents with Immunogen, I transferred the rights to Immunogen. I have not received (and I will not receive) any royalties; I am an inventor in pending patents at Deciphera. I have transferred the rights to Deciphera, I have not received (and will not receive) any royalties
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Sebastian Bauer
Honoraria - Bayer; Deciphera; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar